title: The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer.
abstract: OBJECTIVE
  The results of therapy in 288 men with pathologic Stage C prostate cancer who underwent radical retropubic prostatectomy (RRP) were analyzed to determine the effects of adjuvant therapy.
  
  
  METHODS
  Twenty-seven of the 288 patients received preoperative neoadjuvant hormonal therapy (leuprolide acetate). Postoperatively, 60 patients received adjuvant radiotherapy (RT) to the prostate bed. Follow-up ranged from 3 to 83 months (median = 32 months). Freedom from failure (FFF) was defined as maintaining a serum PSA level of < or = 0.3 ng/ml.
  
  
  RESULTS
  The FFF was 61% at 3 years and 45% at 5 years for the entire group. The FFF following RRP plus RT was 75% at 3 years and 57% at 5 years as compared to 56% at 3 years and 40% at 5 years for RRP without RT (p=0.049). The FFF following RRP plus neoadjuvant hormonal therapy was 58% at 3 years and 40% at 5 years as compared to 60% at 3 years and 45% at 5 years following RRP without hormonal therapy (p=0.3). In patients without seminal vesicle (SV) invasion, the FFF was 81% at 3 years and 5 years for RRP plus RT as compared to 61% at 3 years and 50% at 5 years for RRP without RT (p=0.01). In patients with SV invasion, the FFF was 61% at 3 years and 36% at 5 years for RRP plus RT as compared to 44% at 3 years and 23% at 5 years for RRP without RT (p=0.23). The projected local control rate was 83% at 5 years for those with RRP alone as compared to 100% for RRP plus RT (p=0.02). Survival at 5 years was projected to be 92% and was not significantly altered by the administration of adjuvant therapies.
  
  
  CONCLUSIONS
  Postoperative RT was associated with significantly improved local control and FFF rates, especially in patients with tumors which did not involve the seminal vesicles.
authors.affiliation: Mayo Clinic, Department of Radiation Oncology, Scottsdale, AZ 85259, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Schild
authors.forename: W W
authors.initials: WW
authors.lastname: Wong
authors.forename: G L
authors.initials: GL
authors.lastname: Grado
authors.forename: M Y
authors.initials: MY
authors.lastname: Halyard
authors.forename: D E
authors.initials: DE
authors.lastname: Novicki
authors.forename: S K
authors.initials: SK
authors.lastname: Swanson
authors.forename: T R
authors.initials: TR
authors.lastname: Larson
authors.forename: R G
authors.initials: RG
authors.lastname: Ferrigni
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D017211:Treatment Failure
chemical_list: D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide